Skip to content

Development and application of AI assisted HP diagnosis system under gastroscope

Development and application of AI assisted HP diagnosis system under gastroscope

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037801
Enrollment
Unknown
Registered
2020-09-02
Start date
2020-09-26
Completion date
Unknown
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Development and application of AI assisted HP diagnosis system under gastroscope

Interventions

AI group vs non-AI group:Nil

Sponsors

Department of Gastroenterology, Army Medical Center of PLA (Daping Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age: 18-70 years old, male or female; (2) Urea breath test, rapid urease test, drug sensitivity culture of HP, HP microscopic histological diagnosis, who have completed at least two or more tests, and the test results are consistent; (3) HP can be eradicated in the past, and the withdrawal time should be more than 4 weeks; (4) Sign informed consent.

Exclusion criteria

Exclusion criteria: (1) proton pump inhibitor , antibiotics, histamine-2 receptor antagonist , bismuth, probiotics and other drugs were used within four weeks before the test; (2) Pregnant or lactating women, patients with family planning during the study period; (3) At the same time, they took NSAIDs, corticosteroids, anticoagulants and alcoholism; (4) There are other serious diseases that affect the evaluation of this study, such as severe liver disease, heart disease, kidney disease, malignant tumor, mental disease, etc., which are difficult to tolerate gastroscopy; (5) He had a history of gastric and duodenal ulcer, gastric malignant tumor and other gastric organic lesions; (6) Participated in other drug research in the first three months; (7) It is difficult to complete the follow-up or there are other factors affecting the compliance.

Design outcomes

Primary

MeasureTime frame
Detection rate;accuracy;sensitivity;specificity;

Secondary

MeasureTime frame
Endoscopic operation time;early gastric cancer of detection rate;

Countries

China

Contacts

Public ContactLan Chun-Hui

Department of Gastroenterology, Army Medical Center of PLA (Daping Hospital)

lanchunhui@tmmu.edu.cn+86 023 68757616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026